KRAS and familial pancreatic carcinoma: Our newly developed pan-HDAC inhibitor MPT0E028, which completed phase I clinical trial, in combination with a MEK inhibitor showed a promising antitumor effect for pancreatic cancers especially with a K-Ras mutation.